Deep dive in the new Corporate Tax Haven Index indicators on deductions for intra-group royalty and service fees.

The lithium companies will have to create a new royalty rate proposal, another delay for the commercial extraction of the ...

The lithium companies brought in an army of experts to make the case that their proposed royalty rate is on par with other ...

Choice Hotels' Q3 performance beat expectations, raising the full-year outlook. Learn why CHH stock remains attractive for ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

The Canadian healthcare-focused royalty company said Monday that the royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals was acquired for an ...

Another growth factor is Royalty’s customer attention. “We give them what they want and what they didn’t know they wanted,” Blatt says. That means communicating with customers and spending time with ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

The stock was up 11% to $11.73 on Monday. Shares have jumped 37% over the past 12 months. The pharmaceutical company said the proceeds of the royalty financing deal will be used t ...

October 31, 2024) - EMX Royalty Corporation (NYSE American: EMX) (TSX Venture: EMX) (FSE: 6E9) (the "Company" or "EMX") is ...